Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia

Rebecca J. Deyell, Evan Shereck, Ruth A. Milner, Kirk R. Schultz

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Immunosuppressive therapy (IST) is recommended for children with acquired aplastic anemia (AA) who lack a human leukocyte antigen (HLA)-matched sibling donor for hematopoietic cell transplantation (HCT). Hematopoietic growth factors have often been included in IST supportive care, but prolonged exposure may increase the risk of secondary clonal evolution. The authors evaluated response, survival, and the incidence of clonal evolution following cyclosporine-based IST without hematopoietic growth factor exposure in a population-based pediatric cohort, identified retrospectively. Forty-five patients with a median age of 7.3 years (range 1.217.0 years) were included. Partial (PR) and complete (CR) response was achieved in 82% and 64%, at a median of 55 days (range 11414 days) and 7.6 months (range 2.882.2 months), respectively. Patients with associated seronegative hepatitis had an increased likelihood of PR and CR on multivariate analyses (PR: hazard ratio [HR] 3.15, 95% confidence interval [CI] 1.40, 7.11; CR: HR 2.99, 95% CI 1.35, 6.62), whereas older children were less likely to achieve IST response than children younger than 5 years at diagnosis. Five- and 10-year overall survival was 96% ± 4% and 90% ± 7%, respectively, and 5-year failure-free survival was 63% ± 8%. There was no infection-related mortality, although 16.4% of patients had at least 1 episode of documented bacteremia. The 5-year cumulative incidence of relapse was 12.9% and of clonal evolution was 3.2%. The authors conclude that children with AA who receive IST without hematopoietic growth factor support have excellent response and survival outcomes and a low incidence of clonal evolution.

Original languageEnglish (US)
Pages (from-to)469-478
Number of pages10
JournalPediatric Hematology and Oncology
Volume28
Issue number6
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Aplastic Anemia
Clonal Evolution
Immunosuppressive Agents
Intercellular Signaling Peptides and Proteins
Pediatrics
Survival
Incidence
Confidence Intervals
Therapeutics
Cell Transplantation
HLA Antigens
Bacteremia
Cyclosporine
Hepatitis
Siblings
Multivariate Analysis
Tissue Donors
Recurrence
Mortality
Infection

Keywords

  • Aplastic anemia
  • bone marrow failure
  • hematology
  • nonmalignant
  • supportive care

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia. / Deyell, Rebecca J.; Shereck, Evan; Milner, Ruth A.; Schultz, Kirk R.

In: Pediatric Hematology and Oncology, Vol. 28, No. 6, 09.2011, p. 469-478.

Research output: Contribution to journalArticle

@article{86fc413f865b4c9f9b7310470655be18,
title = "Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia",
abstract = "Immunosuppressive therapy (IST) is recommended for children with acquired aplastic anemia (AA) who lack a human leukocyte antigen (HLA)-matched sibling donor for hematopoietic cell transplantation (HCT). Hematopoietic growth factors have often been included in IST supportive care, but prolonged exposure may increase the risk of secondary clonal evolution. The authors evaluated response, survival, and the incidence of clonal evolution following cyclosporine-based IST without hematopoietic growth factor exposure in a population-based pediatric cohort, identified retrospectively. Forty-five patients with a median age of 7.3 years (range 1.217.0 years) were included. Partial (PR) and complete (CR) response was achieved in 82{\%} and 64{\%}, at a median of 55 days (range 11414 days) and 7.6 months (range 2.882.2 months), respectively. Patients with associated seronegative hepatitis had an increased likelihood of PR and CR on multivariate analyses (PR: hazard ratio [HR] 3.15, 95{\%} confidence interval [CI] 1.40, 7.11; CR: HR 2.99, 95{\%} CI 1.35, 6.62), whereas older children were less likely to achieve IST response than children younger than 5 years at diagnosis. Five- and 10-year overall survival was 96{\%} ± 4{\%} and 90{\%} ± 7{\%}, respectively, and 5-year failure-free survival was 63{\%} ± 8{\%}. There was no infection-related mortality, although 16.4{\%} of patients had at least 1 episode of documented bacteremia. The 5-year cumulative incidence of relapse was 12.9{\%} and of clonal evolution was 3.2{\%}. The authors conclude that children with AA who receive IST without hematopoietic growth factor support have excellent response and survival outcomes and a low incidence of clonal evolution.",
keywords = "Aplastic anemia, bone marrow failure, hematology, nonmalignant, supportive care",
author = "Deyell, {Rebecca J.} and Evan Shereck and Milner, {Ruth A.} and Schultz, {Kirk R.}",
year = "2011",
month = "9",
doi = "10.3109/08880018.2011.568043",
language = "English (US)",
volume = "28",
pages = "469--478",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia

AU - Deyell, Rebecca J.

AU - Shereck, Evan

AU - Milner, Ruth A.

AU - Schultz, Kirk R.

PY - 2011/9

Y1 - 2011/9

N2 - Immunosuppressive therapy (IST) is recommended for children with acquired aplastic anemia (AA) who lack a human leukocyte antigen (HLA)-matched sibling donor for hematopoietic cell transplantation (HCT). Hematopoietic growth factors have often been included in IST supportive care, but prolonged exposure may increase the risk of secondary clonal evolution. The authors evaluated response, survival, and the incidence of clonal evolution following cyclosporine-based IST without hematopoietic growth factor exposure in a population-based pediatric cohort, identified retrospectively. Forty-five patients with a median age of 7.3 years (range 1.217.0 years) were included. Partial (PR) and complete (CR) response was achieved in 82% and 64%, at a median of 55 days (range 11414 days) and 7.6 months (range 2.882.2 months), respectively. Patients with associated seronegative hepatitis had an increased likelihood of PR and CR on multivariate analyses (PR: hazard ratio [HR] 3.15, 95% confidence interval [CI] 1.40, 7.11; CR: HR 2.99, 95% CI 1.35, 6.62), whereas older children were less likely to achieve IST response than children younger than 5 years at diagnosis. Five- and 10-year overall survival was 96% ± 4% and 90% ± 7%, respectively, and 5-year failure-free survival was 63% ± 8%. There was no infection-related mortality, although 16.4% of patients had at least 1 episode of documented bacteremia. The 5-year cumulative incidence of relapse was 12.9% and of clonal evolution was 3.2%. The authors conclude that children with AA who receive IST without hematopoietic growth factor support have excellent response and survival outcomes and a low incidence of clonal evolution.

AB - Immunosuppressive therapy (IST) is recommended for children with acquired aplastic anemia (AA) who lack a human leukocyte antigen (HLA)-matched sibling donor for hematopoietic cell transplantation (HCT). Hematopoietic growth factors have often been included in IST supportive care, but prolonged exposure may increase the risk of secondary clonal evolution. The authors evaluated response, survival, and the incidence of clonal evolution following cyclosporine-based IST without hematopoietic growth factor exposure in a population-based pediatric cohort, identified retrospectively. Forty-five patients with a median age of 7.3 years (range 1.217.0 years) were included. Partial (PR) and complete (CR) response was achieved in 82% and 64%, at a median of 55 days (range 11414 days) and 7.6 months (range 2.882.2 months), respectively. Patients with associated seronegative hepatitis had an increased likelihood of PR and CR on multivariate analyses (PR: hazard ratio [HR] 3.15, 95% confidence interval [CI] 1.40, 7.11; CR: HR 2.99, 95% CI 1.35, 6.62), whereas older children were less likely to achieve IST response than children younger than 5 years at diagnosis. Five- and 10-year overall survival was 96% ± 4% and 90% ± 7%, respectively, and 5-year failure-free survival was 63% ± 8%. There was no infection-related mortality, although 16.4% of patients had at least 1 episode of documented bacteremia. The 5-year cumulative incidence of relapse was 12.9% and of clonal evolution was 3.2%. The authors conclude that children with AA who receive IST without hematopoietic growth factor support have excellent response and survival outcomes and a low incidence of clonal evolution.

KW - Aplastic anemia

KW - bone marrow failure

KW - hematology

KW - nonmalignant

KW - supportive care

UR - http://www.scopus.com/inward/record.url?scp=79958040564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958040564&partnerID=8YFLogxK

U2 - 10.3109/08880018.2011.568043

DO - 10.3109/08880018.2011.568043

M3 - Article

C2 - 21707222

AN - SCOPUS:79958040564

VL - 28

SP - 469

EP - 478

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 6

ER -